Browse the evidence

GLP-1 medicines may suppress tumorigenesis through various mechanisms.

Further research is needed to understand the mechanisms by which GLP-1 medicines may affect tumorigenesis.

GLP-1 RA therapy was associated with a low rate of major adverse events in LVAD patients.

GLP-1 RA appears to be a safe adjunct therapy for LVAD patients.

Ongoing research is crucial to confirm the long-term safety, effectiveness, and clinical role of these agents.

Practitioners should stay updated on research developments regarding these oral agents.

GLP-1 RA therapy was not associated with increased incidence of GI cancers.

GLP-1 RAs may be a safer option regarding GI cancer risk for patients with type 2 diabetes.

No significant differences were observed in biliary cancer or hepatocellular carcinoma between GLP-1 RAs and other oral antidiabetic medications.

Clinicians can consider GLP-1 RAs without increased concern for biliary or liver cancer risks.

Incidental exposure to incretin-based medications during early pregnancy is becoming more likely.

Clinicians should be aware of the risks of medication exposure in unplanned pregnancies.

Both drugs are associated with kidney and thyroid disorders.

Healthcare providers should monitor kidney and thyroid function in patients using these medications.

GLP-1RA development traces a century of translational progress from gut hormones to multi-agonist therapeutics.

Understanding the historical context can inform current therapeutic approaches.

None of the four glucagon-like peptide-1 receptor agonist (GLP-1RA) or glucose-dependent insulinotropic polypeptide (GIP)/GLP-1RA therapies were cost-effective compared with lifestyle management.

Practitioners should consider lifestyle management as the most cost-effective option for treating obesity in this population.

No clinically relevant differences in generic health-related quality of life (HRQoL) were observed between sleeve gastrectomy and Roux-en-Y gastric bypass.

Clinicians can expect similar HRQoL outcomes from both surgical options for patients with severe obesity.

Systematic screening for advanced fibrosis related to MASLD is recommended for patients with T2D.

Healthcare professionals should implement systematic screening for liver fibrosis in diabetic patients.

In women with type 2 diabetes, cardiovascular autonomic neuropathy (CAN) is significantly associated with an increased risk of all-cause mortality (CAN1: HR 1.64, CAN2: HR 1.58, CAN3: HR 1.78) and cardiovascular disease mortality (CAN1: HR 2.25, CAN2: HR 2.22, CAN3: HR 3.31).

Healthcare providers should prioritize monitoring CAN in women with type 2 diabetes to mitigate mortality risk.

Cardiovascular autonomic neuropathy (CAN) is not significantly associated with mortality in men with type 2 diabetes.

Men with type 2 diabetes may require different monitoring strategies for mortality risk compared to women.

There was no association found between weight loss and improvement in FEV1 or FVC.

Weight loss from GLP-1 therapies may not lead to improvements in lung function, indicating the need for further investigation.

Side effects were common and led to discontinuation of the medication in 18.5% of patients.

Clinicians should monitor for side effects in patients on GLP-1 therapies, as they may affect treatment adherence.

Semaglutide would be cost-effective at a threshold of $120,000 per QALY gained if the annual cost were lowered by 18% to $7,055.

Reducing the cost of semaglutide could enhance its affordability and accessibility for patients.

Semaglutide is projected to increase annual health care spending by $23 billion.

Healthcare systems should prepare for increased spending associated with the adoption of semaglutide.

The application of injectable agents is hindered by adverse effects, high costs, and accessibility issues.

Practitioners should consider these barriers when recommending injectable therapies for obesity.

Future pharmacotherapeutic options, including combination therapies and gene therapy, may improve outcomes for patients with genetic obesity disorders.

Practitioners should stay informed about emerging therapies that may enhance treatment for genetic obesity.

Health care expenditures increased by $80 per month during the 13- to 24-month period, excluding the cost of semaglutide.

Practitioners should consider potential increases in health care costs when prescribing semaglutide.

Carbon monoxide (CO) has potential therapeutic applications in obesity treatment.

Practitioners might explore CO-based therapies as innovative options for obesity management.

Obesity is a chronic metabolic disorder that shares underlying pathophysiology with type 2 diabetes mellitus, cardiovascular disease, and diabetic cardiomyopathy.

Understanding the metabolic links can help in developing targeted interventions for obesity and related diseases.

41.9% of the US population is classified as obese.

Practitioners should be aware of the significant prevalence of obesity in the population.

GLP-1 RAs slow both thoracic and abdominal aneurysm growth.

GLP-1 RAs may be beneficial in managing aneurysms in clinical settings.